TransMedics Group (NASDAQ:TMDX) Stock Rating Upgraded by Needham & Company LLC

TransMedics Group (NASDAQ:TMDX) was upgraded by stock analysts at Needham & Company LLC from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Thursday, MarketBeat reports. The brokerage currently has a $148.00 target price on the stock. Needham & Company LLC’s price objective would suggest a potential upside of 13.39% from the stock’s current price.

Other analysts also recently issued research reports about the stock. Canaccord Genuity Group reiterated a “buy” rating and issued a $142.00 target price on shares of TransMedics Group in a report on Tuesday, October 14th. Wall Street Zen raised shares of TransMedics Group from a “hold” rating to a “buy” rating in a research note on Saturday, October 18th. Evercore ISI began coverage on shares of TransMedics Group in a report on Tuesday, September 16th. They issued an “outperform” rating and a $155.00 price objective for the company. Morgan Stanley upped their price objective on shares of TransMedics Group from $115.00 to $123.00 and gave the stock an “equal weight” rating in a report on Friday, August 1st. Finally, Jefferies Financial Group assumed coverage on shares of TransMedics Group in a research report on Monday, October 13th. They set a “buy” rating and a $145.00 price objective on the stock. Eight investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $130.73.

TransMedics Group Stock Performance

Shares of TransMedics Group stock opened at $130.52 on Thursday. The company has a 50 day moving average of $115.94 and a 200-day moving average of $115.23. TransMedics Group has a 1-year low of $55.00 and a 1-year high of $145.50. The company has a current ratio of 9.86, a quick ratio of 9.17 and a debt-to-equity ratio of 1.61. The company has a market cap of $4.45 billion, a PE ratio of 67.63 and a beta of 2.08.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings data on Wednesday, July 30th. The company reported $0.92 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.48 by $0.44. TransMedics Group had a net margin of 13.49% and a return on equity of 28.02%. The business had revenue of $157.37 million during the quarter, compared to analysts’ expectations of $146.64 million. During the same period in the prior year, the company earned $0.35 EPS. The firm’s quarterly revenue was up 37.7% compared to the same quarter last year. TransMedics Group has set its FY 2025 guidance at EPS. As a group, equities research analysts forecast that TransMedics Group will post 1 earnings per share for the current fiscal year.

Institutional Investors Weigh In On TransMedics Group

A number of large investors have recently modified their holdings of TMDX. GAMMA Investing LLC raised its stake in shares of TransMedics Group by 551.7% during the 1st quarter. GAMMA Investing LLC now owns 1,564 shares of the company’s stock worth $105,000 after buying an additional 1,324 shares during the period. Janney Montgomery Scott LLC raised its stake in TransMedics Group by 129.9% in the 1st quarter. Janney Montgomery Scott LLC now owns 8,799 shares of the company’s stock valued at $592,000 after purchasing an additional 4,972 shares during the last quarter. Cambridge Investment Research Advisors Inc. grew its holdings in TransMedics Group by 65.9% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 11,692 shares of the company’s stock valued at $787,000 after buying an additional 4,643 shares in the last quarter. Perigon Wealth Management LLC grew its holdings in TransMedics Group by 31.8% in the 1st quarter. Perigon Wealth Management LLC now owns 18,820 shares of the company’s stock valued at $1,266,000 after buying an additional 4,543 shares in the last quarter. Finally, Lisanti Capital Growth LLC purchased a new stake in TransMedics Group in the 1st quarter valued at $1,942,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.